2022-06-30 18:00:00 CEST

2022-06-30 18:00:08 CEST


REGULATED INFORMATION

English
Oriola Oyj - Other information disclosed according to the rules of the Exchange

Competition authority has given its approval of the merger of Oriola's and Euroapotheca's Swedish pharmacy operations


Oriola Corporation Stock Exchange Release 30 June 2022 at 7.00 p.m.

Competition authority has given its approval of the merger of Oriola's and
Euroapotheca's Swedish pharmacy operations
The Swedish Competition Authority (Konkurrensverket) has given its approval of
the planned merger in which Oriola Corporation and the Euroapotheca group
combine their respective pharmacy businesses in Sweden, Oriola's Kronans Apotek
and Euroapotheca's Apoteksgruppen into a new company. Preparations for the
completion of the merger are ongoing and the completion of the merger is
expected to take place early October 2022.

Oriola announced on 9 February 2022, that it has signed a framework merger
agreement for combining its pharmacy business in Sweden with the respective
Swedish pharmacy business of Euroapotheca. The new company will have over 470
pharmacies and full online pharmacy operations, over 2,300 full-time employees
and an illustrative combined revenue of EUR 1,140 million as of 2020 in Sweden.
The new company is expected to be the third largest player in the Swedish
pharmacy market by revenue, with an estimated combined market share of 25
percent.

Oriola Corporation
Katarina Gabrielson
CEO
Further information:

Katarina Gabrielson
CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com

Tuula Lehto
VP, Communications and Sustainability
tel. +356 40 5885 343
email: Tuula.lehto@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media

Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo, Finland
www.oriola.com